Kirchmeyer v. Helios Psychiatry Inc.

CourtCalifornia Court of Appeal
DecidedMarch 15, 2023
DocketA165128
StatusPublished

This text of Kirchmeyer v. Helios Psychiatry Inc. (Kirchmeyer v. Helios Psychiatry Inc.) is published on Counsel Stack Legal Research, covering California Court of Appeal primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Kirchmeyer v. Helios Psychiatry Inc., (Cal. Ct. App. 2023).

Opinion

Filed 2/14/23; Modified and Certified for Publication 3/15/23 (order attached)

THE COURT OF APPEAL OF THE STATE OF CALIFORNIA

FIRST APPELLATE DISTRICT

DIVISION THREE

KIMBERLY KIRCHMEYER, as Director, etc., A165128 Plaintiff and Respondent, v. (San Francisco City & County Super. Ct. No. CPF-22-517709) HELIOS PSYCHIATRY INC. et al., Defendants and Appellants; REJI VARGHESE, as Deputy Director, etc., Real Party in Interest and Respondent.

While investigating the propriety of psychiatrist Jennifer Dore’s prescription of controlled substances to a family member, the Medical Board of California (Board) — an administrative agency within the Department of Consumer Affairs — served a subpoena and interrogatories on Dr. Dore and her practice, Helios Psychiatry, Inc. (Helios; collectively, Dr. Dore) pursuant to Government Code, section 11180, et seq. (Statutory references are to this code.) After Dr. Dore refused to provide the requested documents and information, the Board petitioned for an order compelling their production. The trial court granted the petition, impliedly concluding the Board

1 established good cause for the disclosure of the private medical information. We affirm. BACKGROUND Dr. Dore is a Board-certified psychiatrist and surgeon, and the founder of Helios. A patient filed a complaint with the Board alleging she inappropriately prescribed controlled substances and violated professional boundaries. The Board opened an investigation and discovered suspected irregularities in the manner in which Dr. Dore prescribed controlled substances. For example, between January 2019 and September 2020, Dr. Dore prescribed two controlled substances — Adderall and Klonopin — to another patient, a family member employed by Helios (family member).1 The Board deemed it necessary to obtain the family member’s medical records to evaluate whether the prescriptions were “medically appropriate and within the standard of care.” The Board interviewed Dr. Dore, but she declined to answer questions about the prescriptions. Thereafter, the Board served her with an investigative subpoena seeking medical records supporting the prescription of the two controlled substances to the family member between January 2019 and September 2020. It also served her with investigative interrogatories requesting information about the treatment she provided to the family member and a description of the family member’s employment at Helios. Dr. Dore refused to produce the records and objected to the interrogatories. Her family member objected to the subpoena on privacy grounds.

1 Other aspects of the Board’s investigation — including its investigation into an allegation that Dr. Dore violated federal regulations by obtaining ketamine prescriptions in her name and using the prescriptions for “office stock” to dispense to patients — are not at issue.

2 Thereafter, the Board petitioned for an order compelling Dr. Dore to comply with the investigative subpoena and interrogatories. It asserted there was a compelling need for the information, and it argued the information was relevant and material to the investigation into whether she complied with the standard of care when prescribing controlled substances to her family member. In a supporting declaration, investigator Michelle Metcalf stated a search of the Controlled Substance Utilization Review and Evaluation System (CURES) database — a repository of prescriptions written for specified controlled substances — revealed Dr. Dore prescribed controlled substances to the family member. Metcalf’s supplemental declaration attached two CURES reports. The first report indicated Dr. Dore prescribed Adderall to the family member six times over an 11-month period, and she prescribed Klonopin twice over a six-month period. The second report showed she prescribed the family member Klonopin and ketamine in 2015 and 2016. The Board retained Board-certified psychiatrist Laura Davies as an expert; she reviewed the CURES reports and opined it was necessary to obtain the family member’s medical records to evaluate whether Dr. Dore complied with the standard of care. In a supporting declaration, Dr. Davies listed her educational history and medical training. She also described the nature of the two controlled substances, their potential complications, and the precautions that should be followed when prescribing them. Further, she attested to her familiarity with the standard of care for the practice of psychiatry, and with the rules, regulations, and standard of care for prescribing controlled substances. She noted an ethics opinion issued by the American Medical Association counseled physicians against treating family members except in emergencies. This admonishment, she explained, applied “with particular emphasis” to

3 psychiatrists as they are required to maintain appropriate boundaries with patients and should not serve in multiple roles. According to Dr. Davies, it is “well understood among psychiatrists, and is part of the training in psychiatry, that treating family members is outside the standard of care. And prescribing controlled substances is in virtually all circumstances, far outside the standard of care.” Dr. Davies opined it was unlikely that an emergency — such as the unavailability of another qualified physician or a health-threatening situation — justified the prescriptions to Dr. Dore’s family member because medical care is widely available in the Bay Area and the family member had no prior prescriptions for the two controlled substances. Moreover, even if an emergency justified the prescriptions, thorough supporting documentation in the medical record would be required. Dr. Davies stated it was important for the Board to obtain the family member’s medical records and Dr. Dore’s interrogatory responses to evaluate her basis for prescribing the controlled substances to the family member, and to determine whether she properly documented the family member’s treatment in the medical record. Dr. Dore opposed the petition to compel compliance with the investigative subpoena and interrogatories. As relevant here, she argued the Board failed to demonstrate either a compelling need for her family member’s constitutionally protected information or good cause for the disclosure. Marvin Firestone, a psychiatrist and licensed California attorney, offered a lengthy declaration disagreeing with Dr. Davies’s assertion that prescribing controlled substances to family members presumptively violates the standard of care. He also challenged the notion that psychiatrists are taught treating family members is outside the standard of care. Referencing several Board publications, Dr. Firestone acknowledged the Board “ ‘discouraged’ ” the

4 practice, but he insisted there was “ ‘no law’ ” prohibiting it. He posited “most physicians treat and prescribe medications to family members,” and noted psychiatrists may decide to treat a family member after considering “myriad” factors, including the family member’s best interest. In Dr. Firestone’s view, the Board failed to demonstrate Dr. Dore’s conduct fell outside the standard of care. In her declaration, Dr. Dore acknowledged physicians are discouraged from treating family members, but she stated the practice is commonplace. She exercised “clinical judgment” when deciding to provide psychiatric services to her family member, and she documented the rationale for her decision in the family member’s medical record, where she also provided a “thorough history, follow-up, and coordination of care.” The family member provided a declaration explaining his reason for seeking treatment from Dr. Dore, identifying the medications she prescribed, and describing the treatment she provided.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

People v. McCary
166 Cal. App. 3d 1 (California Court of Appeal, 1985)
Medical Bd. of Calif. v. Chiarottino
225 Cal. App. 4th 623 (California Court of Appeal, 2014)
Fett v. Medical Board of California
245 Cal. App. 4th 211 (California Court of Appeal, 2016)
Cross v. Superior Court of Los Angeles County
11 Cal. App. 5th 305 (California Court of Appeal, 2017)
Williams v. Superior Court of L. A. Cnty.
398 P.3d 69 (California Supreme Court, 2017)
Lewis v. Superior Court of L. A. Cnty.
397 P.3d 1011 (California Supreme Court, 2017)
Arnett v. Dal Cielo
923 P.2d 1 (California Supreme Court, 1996)
Grafilo v. Wolfsohn
245 Cal. Rptr. 3d 564 (California Court of Appeals, 5th District, 2019)
Kennedy v. Superior Court
248 Cal. Rptr. 3d 441 (California Court of Appeals, 5th District, 2019)

Cite This Page — Counsel Stack

Bluebook (online)
Kirchmeyer v. Helios Psychiatry Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/kirchmeyer-v-helios-psychiatry-inc-calctapp-2023.